MedTrace Logo

AASUR in High Risk Prostate Cancer

NCT02772588 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2026-04-13

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether anti-testosterone medications, when administered before, during, and after high-dose, precision radiation, will be effective in preventing the prostate cancer from returning.

Conditions

Interventions

DRUG

ARN-509

DRUG

Abiraterone

DRUG

Leuprolide

RADIATION

stereotactic, ultra-fractionated radiotherapy

Sponsors & Collaborators

Principal Investigators

  • Sean M McBride, MD, MPH · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-12
Primary Completion
2026-01-22
Completion
2026-01-22

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02772588 on ClinicalTrials.gov